X

Health Care

Syngene reported 21 percent rise in its Q4FY23 net profit

Syngene reported Total revenue for Q4 FY23 of ₹994 Crore, up from ₹759 Crore year on year, a growth of…

Syngene International Q4FY23 results out, revenue rises by 31%

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be…

Nath Bio-Genes (India) Limited (NATHBIOGEN) Q4 FY23 Earnings Concall Transcript

Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Q4 FY23 Earnings Concall dated Apr. 24, 2023. Corporate Participants: Unidentified Speaker -- Devinder Khurana -- Chief Financial…

Panacea Biotec Limited: Making India Healthier

Panacea Biotec Limited is an Indian pharmaceutical company that is engaged in research, development, and manufacturing of pharmaceuticals, vaccines, and…

Shalby Ltd: A rising star in the Anthroplasty surgery

“I am happy to report that our hospital business continued to deliver consistent performance in all key operational and financial…

Can Jubilant Pharmova leverage their position?

“In FY24, Company’s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses.…

Glenmark Pharmaceuticals: An Uphill Battle

“Strategic priority is to enhance our free cash generation and further debt reduction and we continue discussion with potential partners…

Neuland Laboratories Limited Q3 FY23 Earnings Conference Call Insights

Key highlights from Neuland Laboratories Limited (NEULANDLAB) Q3 FY23 Earnings Concall Management Update: [00:05:35] NEULANDLAB said its raw material prices…

Sequent Scientific Limited Q3 FY23 Earnings Conference Call Insights

Key highlights from Sequent Scientific Limited (SEQUENT) Q3 FY23 Earnings Concall Management Update: [00:05:37] SEQUENT said that in the API…

Supriya Lifescience Ltd Q3 FY23 Earnings Conference Call Insights

Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q3 FY23 Earnings Concall Management Update: [00:04:00] SUPRIYA said its primary focus remains…